Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial
Recombinant vectors based on adeno-associated virus serotype 8 (AAV8) have been successfully used in the clinic and hold great promise for liver-directed gene therapy. Preexisting immunity against AAV8 or the development of antibodies against the therapeutic transgene product might negatively affect the outcomes of gene therapy. In the prospect of an AAV8-mediated, liver-directed gene therapy clinical trial for mucopolysaccharidosis VI (MPS VI), a lysosomal storage disorder caused by arylsulfatase B (ARSB) deficiency, we investigated in a multiethnic cohort of MPS VI patients the prevalence of... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Journal article |
Erscheinungsdatum: | 2015 |
Verlag/Hrsg.: |
Mary Ann Liebert
|
Schlagwörter: | Humans / Dependovirus / Mucopolysaccharidosis VI / N-Acetylgalactosamine-4-Sulfatase / Cohort Studies / DNA Mutational Analysis / Cross Reactions / Mutation / Patient Selection / Turkey / Italy / Netherlands / Antibodies / Neutralizing / Genetic Therapy |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26827867 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2440/95182 |